Last reviewed · How we verify
LV009 Injection Infusion — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
LV009 Injection Infusion (LV009 Injection Infusion) — PersonGen BioTherapeutics (Suzhou) Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LV009 Injection Infusion TARGET | LV009 Injection Infusion | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LV009 Injection Infusion CI watch — RSS
- LV009 Injection Infusion CI watch — Atom
- LV009 Injection Infusion CI watch — JSON
- LV009 Injection Infusion alone — RSS
Cite this brief
Drug Landscape (2026). LV009 Injection Infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/lv009-injection-infusion. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing